220 related articles for article (PubMed ID: 24379349)
1. GLP-1/glucagon coagonism restores leptin responsiveness in obese mice chronically maintained on an obesogenic diet.
Clemmensen C; Chabenne J; Finan B; Sullivan L; Fischer K; Küchler D; Sehrer L; Ograjsek T; Hofmann SM; Schriever SC; Pfluger PT; Pinkstaff J; Tschöp MH; Dimarchi R; Müller TD
Diabetes; 2014 Apr; 63(4):1422-7. PubMed ID: 24379349
[TBL] [Abstract][Full Text] [Related]
2. Co-agonist of glucagon and GLP-1 reduces cholesterol and improves insulin sensitivity independent of its effect on appetite and body weight in diet-induced obese C57 mice.
Patel V; Joharapurkar A; Dhanesha N; Kshirsagar S; Patel K; Bahekar R; Shah G; Jain M
Can J Physiol Pharmacol; 2013 Dec; 91(12):1009-15. PubMed ID: 24289070
[TBL] [Abstract][Full Text] [Related]
3. Restoration of leptin responsiveness in diet-induced obese mice using an optimized leptin analog in combination with exendin-4 or FGF21.
Müller TD; Sullivan LM; Habegger K; Yi CX; Kabra D; Grant E; Ottaway N; Krishna R; Holland J; Hembree J; Perez-Tilve D; Pfluger PT; DeGuzman MJ; Siladi ME; Kraynov VS; Axelrod DW; DiMarchi R; Pinkstaff JK; Tschöp MH
J Pept Sci; 2012 Jun; 18(6):383-93. PubMed ID: 22565812
[TBL] [Abstract][Full Text] [Related]
4. Combination of Lorcaserin and GLP-1/glucagon Coagonist Improves Metabolic Dysfunction in Diet Induced-obese Mice.
Patel V; Joharapurkar A; Kshirsagar S; Patel M; Savsani H; Bahekar R; Jain M
Drug Res (Stuttg); 2020 Aug; 70(8):376-384. PubMed ID: 32645724
[TBL] [Abstract][Full Text] [Related]
5. Cannabinoid receptor 1 antagonist treatment induces glucagon release and shows an additive therapeutic effect with GLP-1 agonist in diet-induced obese mice.
Patel KN; Joharapurkar AA; Patel V; Kshirsagar SG; Bahekar R; Srivastava BK; Jain MR
Can J Physiol Pharmacol; 2014 Dec; 92(12):975-83. PubMed ID: 25361428
[TBL] [Abstract][Full Text] [Related]
6. Activation of GLP-1 and Glucagon Receptors Regulates Bile Homeostasis Independent of Thyroid Hormone.
Patel VJ; Joharapurkar AA; Kshirsagar SG; Sutariya BK; Patel MS; Bahekar RH; Jain MR
Curr Mol Pharmacol; 2019; 12(2):139-146. PubMed ID: 30747091
[TBL] [Abstract][Full Text] [Related]
7. Anti-obesity effects of KR-66195, a synthetic DPP-IV inhibitor, in diet-induced obese mice and obese-diabetic ob/ob mice.
Lee EY; Kim YW; Oh H; Choi CS; Ahn JH; Lee BW; Kang ES; Cha BS; Lee HC
Metabolism; 2014 Jun; 63(6):793-9. PubMed ID: 24684824
[TBL] [Abstract][Full Text] [Related]
8. Reversal of obesity and insulin resistance by a non-peptidic glucagon-like peptide-1 receptor agonist in diet-induced obese mice.
He M; Su H; Gao W; Johansson SM; Liu Q; Wu X; Liao J; Young AA; Bartfai T; Wang MW
PLoS One; 2010 Dec; 5(12):e14205. PubMed ID: 21151924
[TBL] [Abstract][Full Text] [Related]
9. Systemic administration of the long-acting GLP-1 derivative NN2211 induces lasting and reversible weight loss in both normal and obese rats.
Larsen PJ; Fledelius C; Knudsen LB; Tang-Christensen M
Diabetes; 2001 Nov; 50(11):2530-9. PubMed ID: 11679431
[TBL] [Abstract][Full Text] [Related]
10. A novel glucagon-like peptide-1/glucagon receptor dual agonist exhibits weight-lowering and diabetes-protective effects.
Zhou J; Cai X; Huang X; Dai Y; Sun L; Zhang B; Yang B; Lin H; Huang W; Qian H
Eur J Med Chem; 2017 Sep; 138():1158-1169. PubMed ID: 28772236
[TBL] [Abstract][Full Text] [Related]
11. Balanced Coagonist of GLP-1 and Glucagon Receptors Corrects Dyslipidemia by Improving FGF21 Sensitivity in Hamster Model.
Patel V; Joharapurkar A; Kshirsagar S; Patel HM; Pandey D; Patel D; Sutariya B; Patel M; Bahekar R; Jain MR
Drug Res (Stuttg); 2017 Dec; 67(12):730-736. PubMed ID: 28898910
[TBL] [Abstract][Full Text] [Related]
12. Exogenous glucagon-like peptide-1 reduces body weight and cholecystokinin-8 enhances this reduction in diet-induced obese male rats.
Mhalhal TR; Washington MC; Newman K; Heath JC; Sayegh AI
Physiol Behav; 2017 Oct; 179():191-199. PubMed ID: 28647503
[TBL] [Abstract][Full Text] [Related]
13. Leptin restores the insulinotropic effect of exenatide in a mouse model of type 2 diabetes with increased adiposity induced by streptozotocin and high-fat diet.
Sakai T; Kusakabe T; Ebihara K; Aotani D; Yamamoto-Kataoka S; Zhao M; Gumbilai VM; Ebihara C; Aizawa-Abe M; Yamamoto Y; Noguchi M; Fujikura J; Hosoda K; Inagaki N; Nakao K
Am J Physiol Endocrinol Metab; 2014 Oct; 307(8):E712-9. PubMed ID: 25159327
[TBL] [Abstract][Full Text] [Related]
14. Pharmacological targeting of glucagon and glucagon-like peptide 1 receptors has different effects on energy state and glucose homeostasis in diet-induced obese mice.
Gu W; Lloyd DJ; Chinookswong N; Komorowski R; Sivits G; Graham M; Winters KA; Yan H; Boros LG; Lindberg RA; Véniant MM
J Pharmacol Exp Ther; 2011 Jul; 338(1):70-81. PubMed ID: 21471191
[TBL] [Abstract][Full Text] [Related]
15. Effects of leptin replacement alone and with exendin-4 on food intake and weight regain in weight-reduced diet-induced obese rats.
Reidelberger R; Haver A; Chelikani PK; Apenteng B; Perriotte-Olson C; Anders K; Steenson S; Blevins JE
Am J Physiol Endocrinol Metab; 2012 Jun; 302(12):E1576-85. PubMed ID: 22510712
[TBL] [Abstract][Full Text] [Related]
16. Glucagon-like peptide-1 receptor agonism improves metabolic, biochemical, and histopathological indices of nonalcoholic steatohepatitis in mice.
Trevaskis JL; Griffin PS; Wittmer C; Neuschwander-Tetri BA; Brunt EM; Dolman CS; Erickson MR; Napora J; Parkes DG; Roth JD
Am J Physiol Gastrointest Liver Physiol; 2012 Apr; 302(8):G762-72. PubMed ID: 22268099
[TBL] [Abstract][Full Text] [Related]
17. Optimization of co-agonism at GLP-1 and glucagon receptors to safely maximize weight reduction in DIO-rodents.
Day JW; Gelfanov V; Smiley D; Carrington PE; Eiermann G; Chicchi G; Erion MD; Gidda J; Thornberry NA; Tschöp MH; Marsh DJ; SinhaRoy R; DiMarchi R; Pocai A
Biopolymers; 2012; 98(5):443-50. PubMed ID: 23203689
[TBL] [Abstract][Full Text] [Related]
18. Coagonist of GLP-1 and Glucagon Receptor Ameliorates Development of Non-Alcoholic Fatty Liver Disease.
Patel V; Joharapurkar A; Kshirsagar S; Sutariya B; Patel M; Patel H; Pandey D; Patel D; Ranvir R; Kadam S; Bahekar R; Jain M
Cardiovasc Hematol Agents Med Chem; 2018; 16(1):35-43. PubMed ID: 29357809
[TBL] [Abstract][Full Text] [Related]
19. A PEGylated analog of the gut hormone oxyntomodulin with long-lasting antihyperglycemic, insulinotropic and anorexigenic activity.
Bianchi E; Carrington PE; Ingallinella P; Finotto M; Santoprete A; Petrov A; Eiermann G; Kosinski J; Marsh DJ; Pocai A; SinhaRoy R; Pessi A
Bioorg Med Chem; 2013 Nov; 21(22):7064-73. PubMed ID: 24094437
[TBL] [Abstract][Full Text] [Related]
20. Amylin improves the effect of leptin on insulin sensitivity in leptin-resistant diet-induced obese mice.
Kusakabe T; Ebihara K; Sakai T; Miyamoto L; Aotani D; Yamamoto Y; Yamamoto-Kataoka S; Aizawa-Abe M; Fujikura J; Hosoda K; Nakao K
Am J Physiol Endocrinol Metab; 2012 Apr; 302(8):E924-31. PubMed ID: 22275759
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
